Cipla Becomes Formosa’s Latest Clobetasol Partner With 11-Country Deal
Exclusive Licensing Agreement For APP13007 Includes India And South Africa
Cipla has bolstered its ophthalmology portfolio and increased its global offering after chalking up an agreement to add Formosa Pharmaceuticals’ USFDA-approved clobetasol propionate 0.05% ophthalmic suspension.
